Comparative Pharmacology
Head-to-head clinical analysis: GENTAMICIN versus KANTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAMICIN versus KANTREX.
GENTAMICIN vs KANTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis; bactericidal against gram-negative aerobes.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
5-7 mg/kg/day IV or IM in divided doses every 8 hours; for serious infections, up to 5 mg/kg/day IV in 3 divided doses.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 24-48 hours in anuria; adjust dosing based on renal function.
Clinical Note
moderateGentamicin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Acetyldigitoxin
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Primarily renal (glomerular filtration): 90-95% unchanged in urine over 24 hours; biliary/fecal: <2%.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Gentamicin."